Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
Dated clinical, regulatory and corporate events for IMAC Holdings, Inc.
How BACK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
No drug pipeline
IMAC Holdings, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Readouts, endpoints and source filings for every BACK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ruiz Jorge10% Owner | Buy | 1 141,230 held | $2.69 | 04/05/2024 |
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BACK for Q2 2026. | ||||
Shares sold short, counted twice a month.
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
How BACK ranks across every disease it competes in